1539. Dalbavancin, Vancomycin, and Daptomycin Alone and in Combination with Cefazolin Against Vancomycin Intermediate-Resistant (VISA) and Daptomycin Non-Susceptible (DNS) Staphylococcus aureus

BACKGROUND: Glycopeptides and lipopeptides, more specifically vancomycin (VAN) and daptomycin (DAP) have been principally utilized in treating MRSA infections. Due to continued use, MRSA strains have developed resistance to these antibiotics including vancomycin intermediate susceptible Staphylococc...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdul-Mutakabbir, Jacinda, Kebriaei, Razieh, Stamper, Kyle, Maassen, Philip, Rybak, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808787/
http://dx.doi.org/10.1093/ofid/ofz360.1403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808787/
http://dx.doi.org/10.1093/ofid/ofz360.1403

Ejemplares similares